Anti-Nardilysin Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibodies targeting Nardilysin (NRDC, EC 3.4.24.61), a mitochondrial metalloprotease involved in neuregulin shedding and dibasic peptide processing.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Rat, Pan, Dog
UniProt
O43847
Size
100ug
Cat. #
RP4Nardilysin

In stock

SKU
RP-Nardilysin

Options

As low as: $130.00

Target Overview

Nardilysin (NRDC, UniProt O43847) is a 1151-residue mitochondrial metalloprotease (EC 3.4.24.61) that cleaves peptide substrates on the N-terminus of arginine residues in dibasic pairs. Also known as N-arginine dibasic convertase (NRD-C), nardilysin functions as a critical activator of BACE1- and ADAM17-mediated pro-neuregulin ectodomain shedding, processes implicated in axonal maturation and myelination. The enzyme is required for proper functioning of 2-oxoglutarate dehydrogenase (OGDH) in mitochondrial metabolism. Nardilysin localizes primarily to mitochondria but has been detected in cytosolic fractions and secreted forms. Its proteolytic activity toward dibasic motifs positions it as a regulatory node in peptide hormone processing and metabolic enzyme activation. Researchers studying neurodevelopment, myelination, mitochondrial function, and metabolic regulation have used nardilysin as both a functional target and a biomarker in clinical cohorts.

Background

Nardilysin plays dual roles in neurobiology and metabolism. As a mitochondrial metalloprotease, it regulates the maturation of neuregulin isoforms by modulating BACE1 and ADAM17 sheddase activity, which in turn affects Schwann cell myelination and peripheral nerve development. Bi-allelic loss-of-function variants in NRDC have been linked to severe neurodevelopmental phenotypes including neonatal lethality, microcephaly, and structural brain abnormalities, underscoring its necessity in human CNS development (Pehlivan et al., 2026). Beyond the nervous system, nardilysin in adipocytes regulates insulin sensitivity through modulation of HIF1α and PPARγ pathways, connecting mitochondrial peptide processing to systemic glucose homeostasis (Matsuda et al., 2025). Recent clinical studies have explored nardilysin as a circulating biomarker in acute cerebrovascular events. Serum nardilysin levels were assessed alongside neurogranin in transient ischemic attack and ischemic stroke cohorts presenting to emergency departments, with associations noted between nardilysin concentrations and early clinical outcomes (Orun et al., 2025; Ozensoy et al., 2025). These findings suggest a potential role for nardilysin as a diagnostic or prognostic marker in stroke, though mechanistic links between mitochondrial enzyme release and vascular pathology remain under investigation. Triple Point Biologics offers four rabbit polyclonal antibodies raised against the amino-terminal region of nardilysin, validated in human samples by Western blot. Cross-reactivity with rat, non-human primate, and canine orthologs is predicted based on sequence homology but requires empirical confirmation.

References

  1. Pehlivan D et al (2026) Bi-allelic variants in NRDC cause a neurodevelopmental disorder characterized by neonatal lethality, microcephaly, and brain abnormalities. Am J Hum Genet. PubMed · DOI
  2. Matsuda S et al (2025) Nardilysin in adipocyte regulates insulin sensitivity via HIF1α and PPARγ. Sci Rep. PubMed · DOI
  3. Orun S et al (2025) Association of blood nardilysin and neurogranin levels with early outcomes in transient ischemic attack: A prospective cohort study. Medicine (Baltimore). PubMed · DOI
  4. Ozensoy HS et al (2025) Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study Conducted in the Emergency Department. Med Sci Monit. PubMed · DOI

Additional Specifications

Gene Symbol NRDC
UniProt ID O43847
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Rat, Pan, Dog
Pack Size 100ug
Immunogen (Amino end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 21-71.
Immunogen (Catalytic domain insert)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 21-1151.
Immunogen (Â inactive protease domains)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 21-1151.
Immunogen (Carboxyterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 1101-1151.
Alternate Names NRDC, N-arginine dibasic convertase, Nardilysin convertase, NRD convertase, NRD-C, EC 3.4.24.61

Frequently Asked Questions

What molecular weight should I expect for nardilysin on a Western blot?

Nardilysin migrates at approximately 130 kDa on SDS-PAGE, consistent with its 1151-residue sequence (predicted MW ~127 kDa). You may observe additional bands around 110-120 kDa representing proteolytic fragments or alternatively processed forms, particularly in mitochondrial-enriched fractions. Some reports describe a cleaved cytosolic form that lacks the N-terminal mitochondrial targeting sequence. If you see multiple bands, consider whether your sample preparation retained full-length protein; harsh lysis conditions or freeze-thaw cycles can promote cleavage. Running a parallel lane with recombinant nardilysin or a well-characterized positive-control lysate helps confirm identity.

What starting dilution should I use for nardilysin Western blots?

Start at 1:1000 dilution in blocking buffer containing 5 percent non-fat milk or BSA. Nardilysin is moderately abundant in brain, heart, and metabolically active tissues but lower in many cell lines, so you may need to optimize between 1:500 and 1:2000 depending on your sample. Incubate overnight at four degrees Celsius for best signal-to-noise. Load 20-40 micrograms total protein per lane; mitochondrial-enriched fractions typically yield stronger signals than whole-cell lysates. If background is high at 1:1000, increase dilution and extend exposure time rather than reducing antibody concentration too quickly.

Does nardilysin localize to mitochondria or cytosol, and how does that affect sample prep?

Nardilysin is primarily mitochondrial but detectable in cytosolic fractions and secreted forms depending on cell type and metabolic state. For strongest signal, use mitochondrial-enrichment protocols or whole-cell RIPA lysis with protease inhibitors. Avoid hypotonic buffers that may rupture mitochondria incompletely, leaving nardilysin in pellet fractions. If studying ectodomain shedding or neuregulin activation, include conditioned media or membrane preparations. Subcellular fractionation can clarify whether you are detecting full-length mitochondrial nardilysin or cleaved cytosolic isoforms. Always include a mitochondrial marker like VDAC or COX IV to verify fraction purity.

Is this nardilysin antibody cross-reactive with rat and mouse samples?

Human nardilysin is validated; rat and mouse cross-reactivity are predicted based on sequence homology exceeding 85 percent in the immunogen region. Researchers have successfully used rabbit polyclonal nardilysin antibodies on rodent brain and heart lysates, but we recommend titrating dilution and running a positive control the first time. Expect similar banding patterns around 130 kDa. If signal is weak in mouse samples, consider enriching mitochondria or increasing protein load to 40 micrograms per lane. Canine cross-reactivity is also predicted but less commonly reported; empirical validation in your tissue of interest is prudent.

What are good positive and negative controls for nardilysin Western blots?

Brain, heart, and liver lysates serve as strong positive controls because nardilysin is expressed at moderate to high levels in metabolically active tissues. Neuronal cell lines like SH-SY5Y or primary cortical cultures also work well, especially if you are studying neuregulin signaling. HEK293 or COS cells transfected with nardilysin expression constructs provide an unambiguous positive band. For negative controls, consider NRDC-knockout cell lines if available, or tissues with very low endogenous expression. Recombinant nardilysin protein, when run alongside lysates, confirms antibody specificity and helps distinguish full-length from cleaved forms.

Can I use this antibody for immunofluorescence or immunohistochemistry on nardilysin?

Triple Point Biologics antibodies are routinely validated for immunohistochemistry and immunofluorescence alongside Western blot. For IF, try 1:100 to 1:200 dilution; nardilysin should show punctate mitochondrial staining that co-localizes with MitoTracker or TOM20. Antigen retrieval—citrate buffer, pH six, ten minutes at sub-boiling—improves IHC signal in formalin-fixed paraffin sections, particularly in brain and cardiac tissue. Expect cytoplasmic and perinuclear signal. Methanol fixation often works better than paraformaldehyde for preserving mitochondrial epitopes in cultured cells. Include a no-primary-antibody control to assess non-specific secondary binding.

How should I store the nardilysin antibody and how long is it stable?

Store at minus twenty degrees Celsius in single-use aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The 100-microgram pack size is convenient for aliquoting 10-20 microliter volumes in working dilution or as concentrated stock. Antibody remains stable for at least twelve months under these conditions. For short-term use within two to four weeks, you may hold aliquots at four degrees Celsius in the presence of 0.02 percent sodium azide or commercial stabilizer; however, freezing is preferable for long-term preservation. Do not store in frost-free freezers that undergo temperature cycling.

Does nardilysin have isoforms or splice variants I should be aware of?

The canonical nardilysin transcript encodes the 1151-residue isoform. Alternative splicing has been reported but is not well characterized in most tissues. You may detect proteolytic cleavage products, particularly a truncated form missing the N-terminal mitochondrial import sequence that appears in cytosolic fractions. These fragments retain catalytic activity and are biologically relevant. On Western blots, minor bands below 130 kDa likely represent such cleavage events rather than distinct splice isoforms. If you are comparing tissues or disease models, expect variation in the ratio of full-length to cleaved nardilysin, which can reflect differences in mitochondrial integrity or proteolytic regulation.

Western blot validation for RP-Nardilysin — 4 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Nardilysin: Amino end — WB validation
WB · Panel 1 Nardilysin: Amino end
Nardilysin: Catalytic domain insert — WB validation
WB · Panel 2 Nardilysin: Catalytic domain insert
Nardilysin: Â inactive protease domains — WB validation
WB · Panel 3 Nardilysin: Â inactive protease domains
Nardilysin: Carboxyterminal end — WB validation
WB · Panel 4 Nardilysin: Carboxyterminal end

Custom validation studies available on request — contact us.

Also known as:

  • NRDC
  • N-arginine dibasic convertase
  • Nardilysin convertase
  • NRD convertase
  • NRD-C
  • EC 3.4.24.61
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →